Changelog
Every page added to the pipeline tracker, newest first. The database is rebuilt into the site daily, so a compound added today appears here within 24 hours.
135 compounds·191 programs·51 indications·81 companies
August 202676 pages
Compounds (27)
- AL001 (lithium–salicylate–L-proline)
- AP707
- AVP-786 (deudextromethorphan-quinidine)
- Crenezumab
- Dalzanemdor
- Evenamide
- Fazamorexant (YZJ-1139)
- Gantenerumab
- Latozinemab
- Masitinib
- Mavoglurant
- ND0612 (levodopa/carbidopa continuous subcutaneous infusion)
- NS-136
- Osoresnontrine
- Pomaglumetad methionil
- PT00114
- Ralmitaront
- Rapastinel
- Rotigotine extended-release microspheres (LY03003)
- Sipagladenant
- Solanezumab
- SPN-810 (molindone ER)
- Tolebrutinib
- Vixotrigine
- Xanomeline/trospium chloride (Cobenfy)
- Zatolmilast
- Zervimesine
Programs (42)
- AL001 (lithium–salicylate–L-proline) for Alzheimer's disease
- AL001 (lithium–salicylate–L-proline) for Bipolar disorder
- AP707 for Neuropathic pain
- AVP-786 (deudextromethorphan-quinidine) for Agitation in Alzheimer's disease
- AVP-786 (deudextromethorphan-quinidine) for Schizophrenia
- AVP-786 (deudextromethorphan-quinidine) for Treatment-resistant depression
- Crenezumab for Alzheimer's disease
- Dalzanemdor for Alzheimer's disease
- Dalzanemdor for Huntington's disease
- Dalzanemdor for Parkinson's disease
- Evenamide for Schizophrenia
- Fazamorexant (YZJ-1139) for Insomnia
- Gantenerumab for Alzheimer's disease
- Latozinemab for Amyotrophic lateral sclerosis
- Latozinemab for Frontotemporal dementia
- Masitinib for Alzheimer's disease
- Masitinib for Amyotrophic lateral sclerosis
- Masitinib for Multiple sclerosis
- Mavoglurant for Cocaine use disorder
- Mavoglurant for Fragile X syndrome
- Mavoglurant for Huntington's disease
- Mavoglurant for Obsessive-compulsive disorder
- ND0612 (levodopa/carbidopa continuous subcutaneous infusion) for Parkinson's disease
- NS-136 for Schizophrenia
- Osoresnontrine for Alzheimer's disease
- Osoresnontrine for Schizophrenia
- Pomaglumetad methionil for Schizophrenia
- PT00114 for Generalized anxiety disorder
- Ralmitaront for Schizophrenia
- Rapastinel for Major depressive disorder
- Rotigotine extended-release microspheres (LY03003) for Parkinson's disease
- Sipagladenant for Parkinson's disease
- Solanezumab for Alzheimer's disease
- SPN-810 (molindone ER) for Attention-deficit/hyperactivity disorder
- Tolebrutinib for Multiple sclerosis
- Vixotrigine for Neuropathic pain
- Xanomeline/trospium chloride (Cobenfy) for Alzheimer's disease psychosis
- Xanomeline/trospium chloride (Cobenfy) for Schizophrenia
- Zatolmilast for Alzheimer's disease
- Zatolmilast for Fragile X syndrome
- Zervimesine for Alzheimer's disease
- Zervimesine for Lewy body dementia
July 202645 pages
Compounds (15)
Programs (19)
- Atuzaginstat (COR388) for Alzheimer's disease
- CN-105 for Intracerebral hemorrhage
- CN-105 for Postoperative delirium
- DT-101 for Major depressive disorder
- ENX-104 for Major depressive disorder
- Forvisirvat for Major depressive disorder
- KYN-5356 for Schizophrenia
- LHP588 for Alzheimer's disease
- LPCN 1154 (oral brexanolone) for Postpartum depression
- Luvesilocin (RE104) for Generalized anxiety disorder
- Luvesilocin (RE104) for Postpartum depression
- ML-007C-MA for Alzheimer's disease psychosis
- ML-007C-MA for Schizophrenia
- Nelivaptan (BH-200) for Major depressive disorder
- NTX-1472 for Social anxiety disorder
- Remlifanserin for Alzheimer's disease psychosis
- Remlifanserin for Lewy body dementia psychosis
- Ropanicant for Major depressive disorder
- Zalsupindole (DLX-001) for Major depressive disorder
Indications (4)
June 2026337 pages
Compounds (93)
- AEF0117 (lixosicone)
- AEF0217
- Alixorexton
- ALTO-100 (amdiglurax)
- ALTO-101
- ALTO-203
- ALTO-207
- ALTO-300 (agomelatine)
- Ammoxetine (S-071031B)
- Apimostinel (GATE-202)
- Aticaprant
- AXS-05 (dextromethorphan-bupropion)
- AXS-12 (reboxetine)
- AXS-14 (esreboxetine)
- Azetukalner (XEN1101)
- BHV-2100
- BHV-8000
- BI 1358894
- BI 1569912
- Blixeprodil (GM-1020)
- BNC210 (soclenicant)
- BPL-003 (intranasal 5-MeO-DMT benzoate)
- Bretisilocin (GM-2505)
- Brexpiprazole
- Brezivaptan (TS-121 / ANC-501)
- Brilaroxazine (RP5063)
- Centanafadine
- CYB003 (deupsilocin)
- CYB004 (deuterated DMT)
- Darigabat (CVL-865)
- Dexmedetomidine sublingual film (BXCL501)
- Direclidine (NBI-1117568)
- DT402
- Ecopipam
- ELE-101 (intravenous psilocin benzoate)
- Elpipodect (MK-8189)
- Elunetirom (ABX-002)
- EMP-01 (oral R-MDMA)
- Emraclidine (CVL-231)
- Emrusolmin
- Enerisant (TS-091)
- Esmethadone (REL-1017)
- Fasedienol (PH94B)
- GlyphAllo (SPT-300)
- Icalcaprant
- Iclepertin (BI 425809)
- Iloperidone LAI
- ITI-1284 (deulumateperone)
- Itruvone
- JNJ-2056 (ACI-35.030)
- LB-102 (N-methylamisulpride)
- Lenrispodun (ITI-214)
- Lumateperone (ITI-007)
- LUMRYZ (sodium oxybate extended-release)
- Luvadaxistat (TAK-831)
- LYBALVI (olanzapine/samidorphan)
- Lysergide D-tartrate (MM120 / LSD)
- Mebufotenin (inhaled 5-MeO-DMT, GH001)
- Mefluleucine (NV-5138)
- Methylone (TSND-201)
- Milsaperidone (VHX-896)
- MK-1167
- MK-1942
- MK-2214
- MSP-1014
- Navacaprant (NMRA-140)
- NBI-1065890
- NBI-1070770
- NBI-1117570
- NMRA-511
- Olanzapine extended-release injectable suspension (TEV-'749)
- Opakalim (BHV-7000)
- OPC-64005
- Osavampator (NBI-1065845)
- Oveporexton
- Posdinemab
- Psilocybin (COMP360)
- Roluperidone (MIN-101)
- Seltorexant (JNJ-42847922)
- Sepranolone
- Solriamfetol (Sunosi)
- TAK-360
- Tavapadon
- TNX-102 SL (cyclobenzaprine HCl sublingual)
- TNX-1900
- Troriluzole (BHV-4157)
- TS-161
- Ulefnersen (ION363)
- Ulotaront (SEP-363856)
- VLS-01
- Vornorexant (TS-142)
- VQW-765
- Zelquistinel (GATE-251)
Programs (130)
- AEF0117 (lixosicone) for Cannabis use disorder
- AEF0217 for Down Syndrome
- Alixorexton for Idiopathic Hypersomnia
- Alixorexton for Narcolepsy
- ALTO-100 (amdiglurax) for Bipolar depression
- ALTO-101 for Schizophrenia
- ALTO-203 for Major depressive disorder
- ALTO-207 for Treatment-resistant depression
- ALTO-300 (agomelatine) for Major depressive disorder
- Ammoxetine (S-071031B) for Major depressive disorder
- Apimostinel (GATE-202) for Major depressive disorder
- Aticaprant for Major depressive disorder
- AXS-05 (dextromethorphan-bupropion) for Agitation in Alzheimer's disease
- AXS-05 (dextromethorphan-bupropion) for Tobacco use disorder
- AXS-12 (reboxetine) for Narcolepsy
- AXS-14 (esreboxetine) for Fibromyalgia
- Azetukalner (XEN1101) for Bipolar depression
- Azetukalner (XEN1101) for Epilepsy
- Azetukalner (XEN1101) for Major depressive disorder
- BHV-2100 for Migraine
- BHV-8000 for Parkinson's disease
- BI 1358894 for Major depressive disorder
- BI 1569912 for Major depressive disorder
- Blixeprodil (GM-1020) for Major depressive disorder
- BNC210 (soclenicant) for Post-traumatic stress disorder
- BNC210 (soclenicant) for Social anxiety disorder
- BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol use disorder
- BPL-003 (intranasal 5-MeO-DMT benzoate) for Treatment-resistant depression
- Bretisilocin (GM-2505) for Major depressive disorder
- Brexpiprazole for Post-traumatic stress disorder
- Brezivaptan (TS-121 / ANC-501) for Major depressive disorder
- Brilaroxazine (RP5063) for Schizophrenia
- Centanafadine for Attention-deficit/hyperactivity disorder
- CYB003 (deupsilocin) for Major depressive disorder
- CYB004 (deuterated DMT) for Generalized anxiety disorder
- Darigabat (CVL-865) for Epilepsy
- Dexmedetomidine sublingual film (BXCL501) for Acute Stress Disorder
- Dexmedetomidine sublingual film (BXCL501) for Agitation in Alzheimer's disease
- Dexmedetomidine sublingual film (BXCL501) for Opioid use disorder
- Dexmedetomidine sublingual film (BXCL501) for Schizophrenia
- Direclidine (NBI-1117568) for Bipolar disorder
- Direclidine (NBI-1117568) for Schizophrenia
- DT402 for Autism spectrum disorder
- Ecopipam for Tourette syndrome
- ELE-101 (intravenous psilocin benzoate) for Major depressive disorder
- Elpipodect (MK-8189) for Schizophrenia
- Elunetirom (ABX-002) for Bipolar depression
- Elunetirom (ABX-002) for Major depressive disorder
- EMP-01 (oral R-MDMA) for Social anxiety disorder
- Emraclidine (CVL-231) for Schizophrenia
- Emrusolmin for Multiple System Atrophy
- Enerisant (TS-091) for Narcolepsy
- Esmethadone (REL-1017) for Major depressive disorder
- Fasedienol (PH94B) for Social anxiety disorder
- GlyphAllo (SPT-300) for Major depressive disorder
- Icalcaprant for Major depressive disorder
- Iclepertin (BI 425809) for Schizophrenia
- Iloperidone LAI for Schizophrenia
- ITI-1284 (deulumateperone) for Agitation in Alzheimer's disease
- ITI-1284 (deulumateperone) for Alzheimer's disease
- ITI-1284 (deulumateperone) for Generalized anxiety disorder
- Itruvone for Major depressive disorder
- JNJ-2056 (ACI-35.030) for Alzheimer's disease
- LB-102 (N-methylamisulpride) for Bipolar depression
- LB-102 (N-methylamisulpride) for Major depressive disorder
- LB-102 (N-methylamisulpride) for Schizophrenia
- Lenrispodun (ITI-214) for Parkinson's disease
- Lumateperone (ITI-007) for Autism spectrum disorder
- Lumateperone (ITI-007) for Bipolar depression
- Lumateperone (ITI-007) for Bipolar disorder
- Lumateperone (ITI-007) for Major depressive disorder
- Lumateperone (ITI-007) for Schizophrenia
- LUMRYZ (sodium oxybate extended-release) for Idiopathic Hypersomnia
- Luvadaxistat (TAK-831) for Schizophrenia
- LYBALVI (olanzapine/samidorphan) for Schizophrenia
- Lysergide D-tartrate (MM120 / LSD) for Attention-deficit/hyperactivity disorder
- Lysergide D-tartrate (MM120 / LSD) for Generalized anxiety disorder
- Lysergide D-tartrate (MM120 / LSD) for Major depressive disorder
- Lysergide D-tartrate (MM120 / LSD) for Post-traumatic stress disorder
- Mebufotenin (inhaled 5-MeO-DMT, GH001) for Bipolar depression
- Mebufotenin (inhaled 5-MeO-DMT, GH001) for Postpartum depression
- Mebufotenin (inhaled 5-MeO-DMT, GH001) for Treatment-resistant depression
- Mefluleucine (NV-5138) for Treatment-resistant depression
- Methylone (TSND-201) for Post-traumatic stress disorder
- Milsaperidone (VHX-896) for Bipolar disorder
- Milsaperidone (VHX-896) for Major depressive disorder
- MK-1167 for Alzheimer's disease
- MK-1942 for Treatment-resistant depression
- MK-2214 for Alzheimer's disease
- MSP-1014 for Major depressive disorder
- Navacaprant (NMRA-140) for Major depressive disorder
- NBI-1065890 for Tardive Dyskinesia
- NBI-1070770 for Major depressive disorder
- NBI-1117570 for Schizophrenia
- NMRA-511 for Agitation in Alzheimer's disease
- Olanzapine extended-release injectable suspension (TEV-'749) for Schizophrenia
- Opakalim (BHV-7000) for Bipolar disorder
- Opakalim (BHV-7000) for Epilepsy
- Opakalim (BHV-7000) for Major depressive disorder
- OPC-64005 for Major depressive disorder
- Osavampator (NBI-1065845) for Major depressive disorder
- Oveporexton for Narcolepsy
- Posdinemab for Alzheimer's disease
- Psilocybin (COMP360) for Anorexia nervosa
- Psilocybin (COMP360) for Major depressive disorder
- Psilocybin (COMP360) for Post-traumatic stress disorder
- Psilocybin (COMP360) for Treatment-resistant depression
- Roluperidone (MIN-101) for Schizophrenia
- Seltorexant (JNJ-42847922) for Major depressive disorder
- Sepranolone for Tourette syndrome
- Solriamfetol (Sunosi) for Attention-deficit/hyperactivity disorder
- Solriamfetol (Sunosi) for Binge eating disorder
- Solriamfetol (Sunosi) for Excessive daytime sleepiness
- Solriamfetol (Sunosi) for Major depressive disorder
- TAK-360 for Narcolepsy
- Tavapadon for Parkinson's disease
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Acute Stress Disorder
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Fibromyalgia
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Major depressive disorder
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Post-traumatic stress disorder
- TNX-1900 for Migraine
- Troriluzole (BHV-4157) for Obsessive-compulsive disorder
- TS-161 for Treatment-resistant depression
- Ulefnersen (ION363) for Amyotrophic lateral sclerosis
- Ulotaront (SEP-363856) for Generalized anxiety disorder
- Ulotaront (SEP-363856) for Major depressive disorder
- VLS-01 for Treatment-resistant depression
- Vornorexant (TS-142) for Insomnia
- VQW-765 for Social anxiety disorder
- Zelquistinel (GATE-251) for Major depressive disorder
Indications (47)
- Acute Stress Disorder
- Agitation in Alzheimer's disease
- Alcohol use disorder
- Alzheimer's disease
- Amyotrophic lateral sclerosis
- Anorexia nervosa
- Attention-deficit/hyperactivity disorder
- Autism spectrum disorder
- Binge eating disorder
- Bipolar depression
- Bipolar disorder
- Cannabis use disorder
- Cocaine use disorder
- Down Syndrome
- Epilepsy
- Excessive daytime sleepiness
- Fibromyalgia
- Fragile X syndrome
- Frontotemporal dementia
- Generalized anxiety disorder
- Huntington's disease
- Idiopathic Hypersomnia
- Insomnia
- Lewy body dementia
- Major depressive disorder
- Migraine
- Multiple sclerosis
- Multiple System Atrophy
- Narcolepsy
- Neuropathic pain
- Obsessive-compulsive disorder
- Opioid use disorder
- Panic disorder
- Parkinson's disease
- Parkinson's disease psychosis
- Post-traumatic stress disorder
- Postpartum depression
- Rett syndrome
- Schizoaffective disorder
- Schizophrenia
- Social anxiety disorder
- Stimulant use disorder
- Suicidal ideation
- Tardive Dyskinesia
- Tobacco use disorder
- Tourette syndrome
- Treatment-resistant depression
Companies (67)
- AB Science
- AC Immune SA
- ACADIA Pharmaceuticals Inc.
- Aelis Farma S.A.
- Alector Inc.
- Alkermes plc
- Alto Neuroscience, Inc.
- Alzamend Neuro, Inc.
- Atai Beckley N.V. (AtaiBeckley)
- Autobahn Therapeutics, Inc.
- Avanir Pharmaceuticals
- Axsome Therapeutics, Inc.
- Beckley Psytech Limited
- Biohaven Ltd.
- BioXcel Therapeutics, Inc.
- Boehringer Ingelheim
- Cerevel Therapeutics Holdings, Inc.
- Cognition Therapeutics, Inc.
- COMPASS Pathways plc
- Convergence Pharmaceuticals
- CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
- Definium Therapeutics, Inc.
- Draig Therapeutics Ltd
- Eli Lilly and Company
- Emalex Biosciences Inc.
- EmpathBio, Inc.
- F. Hoffmann-La Roche Ltd
- GH Research PLC
- Gilgamesh Pharmaceuticals, Inc.
- Helus Pharma
- Intra-Cellular Therapies, Inc.
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Karuna Therapeutics
- Kyowa Kirin Co., Ltd.
- LB Pharmaceuticals Inc.
- MapLight Therapeutics, Inc.
- Merck & Co., Inc.
- Mindset Pharma Inc.
- Minerva Neurosciences, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Naurex, Inc.
- Navitor Pharmaceuticals, Inc.
- Neumora Therapeutics, Inc.
- Neuphoria Therapeutics, Inc.
- Neurocrine Biosciences, Inc.
- NeuShen Therapeutics
- Novartis Pharma AG
- Otsuka Pharmaceutical Co., Ltd.
- Pherin Pharmaceuticals, Inc.
- Relmada Therapeutics, Inc.
- Reunion Neuroscience Inc.
- Reviva Pharmaceuticals Holdings, Inc.
- Sage Therapeutics, Inc.
- Sanofi
- Seaport Therapeutics, Inc.
- Supernus Pharmaceuticals, Inc.
- Syndeio Biosciences, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Tetra Discovery Partners
- Teva Pharmaceutical Industries Ltd.
- Tonix Pharmaceuticals Holding Corp.
- Transcend Therapeutics, Inc.
- Vanda Pharmaceuticals Inc.
- Vistagen Therapeutics, Inc.
- Xenon Pharmaceuticals Inc.
Dated by when the record entered the database. Pages are revised as new sources appear — those revisions are not listed here, only first publication. Last built September 18, 2026.